A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs BMS 813160 (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Apr 2019 Planned End Date changed from 31 Jan 2026 to 31 Jan 2025.
- 19 Apr 2019 Planned primary completion date changed from 31 Jan 2026 to 31 Jan 2025.
- 05 Sep 2018 Planned End Date changed from 28 Feb 2026 to 31 Jan 2026.